BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
NYSE:BIO - New York Stock Exchange, Inc. - US0905722072 - Common Stock - Currency: USD
Taking everything into account, BIO scores 4 out of 10 in our fundamental rating. BIO was compared to 55 industry peers in the Life Sciences Tools & Services industry. BIO has an excellent financial health rating, but there are some minor concerns on its profitability. BIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
BIO had positive earnings in the past year.
BIO had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
In the past 5 years BIO always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of -22.71%, BIO is doing worse than 65.45% of the companies in the same industry.
With a Return On Equity value of -32.40%, BIO is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
BIO has a better Return On Invested Capital (2.70%) than 61.82% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIO is significantly below the industry average of 13.60%.
The last Return On Invested Capital (2.70%) for BIO is above the 3 year average (2.69%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.71% | ||
| ROE | -32.4% | ||
| ROIC | 2.7% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
With a decent Operating Margin value of 12.14%, BIO is doing good in the industry, outperforming 69.09% of the companies in the same industry.
BIO's Operating Margin has been stable in the last couple of years.
BIO's Gross Margin of 53.68% is fine compared to the rest of the industry. BIO outperforms 61.82% of its industry peers.
In the last couple of years the Gross Margin of BIO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.14% | ||
| PM (TTM) | N/A | ||
| GM | 53.68% |
OM growth 3Y-15.52%
OM growth 5Y1.14%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO is destroying value.
Compared to 1 year ago, BIO has less shares outstanding
BIO has less shares outstanding than it did 5 years ago.
The debt/assets ratio for BIO is higher compared to a year ago.
2.2 Solvency
BIO has an Altman-Z score of 3.13. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
BIO's Altman-Z score of 3.13 is fine compared to the rest of the industry. BIO outperforms 63.64% of its industry peers.
The Debt to FCF ratio of BIO is 3.62, which is a good value as it means it would take BIO, 3.62 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.62, BIO is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
A Debt/Equity ratio of 0.18 indicates that BIO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.18, BIO perfoms like the industry average, outperforming 58.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.62 | ||
| Altman-Z | 3.13 |
ROIC/WACC0.28
WACC9.74%
2.3 Liquidity
A Current Ratio of 5.99 indicates that BIO has no problem at all paying its short term obligations.
BIO has a better Current ratio (5.99) than 81.82% of its industry peers.
A Quick Ratio of 4.43 indicates that BIO has no problem at all paying its short term obligations.
BIO's Quick ratio of 4.43 is fine compared to the rest of the industry. BIO outperforms 70.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.99 | ||
| Quick Ratio | 4.43 |
3. Growth
3.1 Past
The earnings per share for BIO have decreased by -1.49% in the last year.
Measured over the past 5 years, BIO shows a small growth in Earnings Per Share. The EPS has been growing by 7.84% on average per year.
BIO shows a decrease in Revenue. In the last year, the revenue decreased by -2.46%.
Measured over the past years, BIO shows a small growth in Revenue. The Revenue has been growing by 2.11% on average per year.
EPS 1Y (TTM)-1.49%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%10.92%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%-4.16%
3.2 Future
BIO is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.33% yearly.
BIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.35% yearly.
EPS Next Y-15.61%
EPS Next 2Y-3.01%
EPS Next 3Y2.58%
EPS Next 5Y-4.33%
Revenue Next Year-2.11%
Revenue Next 2Y0.75%
Revenue Next 3Y1.79%
Revenue Next 5Y1.35%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BIO is valuated rather expensively with a Price/Earnings ratio of 21.49.
Based on the Price/Earnings ratio, BIO is valued a bit cheaper than the industry average as 78.18% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.31, BIO is valued at the same level.
With a Price/Forward Earnings ratio of 23.40, BIO is valued on the expensive side.
BIO's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BIO is cheaper than 70.91% of the companies in the same industry.
BIO is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.13, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.49 | ||
| Fwd PE | 23.4 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO is valued cheaper than 83.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.14 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)2.74
EPS Next 2Y-3.01%
EPS Next 3Y2.58%
5. Dividend
5.1 Amount
BIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
226.91
-5.51 (-2.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.78%
Inst Owner Change-1.39%
Ins Owners3.67%
Ins Owner Change0%
Market Cap6.36B
Analysts76.36
Price Target324.19 (42.87%)
Short Float %6.81%
Short Ratio3.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.53%
Min EPS beat(2)0.1%
Max EPS beat(2)38.97%
EPS beat(4)4
Avg EPS beat(4)40.99%
Min EPS beat(4)0.1%
Max EPS beat(4)72.05%
EPS beat(8)7
Avg EPS beat(8)21.55%
EPS beat(12)8
Avg EPS beat(12)14.41%
EPS beat(16)12
Avg EPS beat(16)19.4%
Revenue beat(2)1
Avg Revenue beat(2)-0.8%
Min Revenue beat(2)-2.71%
Max Revenue beat(2)1.11%
Revenue beat(4)2
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)2.41%
Revenue beat(8)2
Avg Revenue beat(8)-2.22%
Revenue beat(12)3
Avg Revenue beat(12)-1.99%
Revenue beat(16)6
Avg Revenue beat(16)0.12%
PT rev (1m)-2.8%
PT rev (3m)-13.98%
EPS NQ rev (1m)-2.45%
EPS NQ rev (3m)-28.27%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.49 | ||
| Fwd PE | 23.4 | ||
| P/S | 2.5 | ||
| P/FCF | 19.14 | ||
| P/OCF | 12.34 | ||
| P/B | 0.95 | ||
| P/tB | 1.06 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.56
EY4.65%
EPS(NY)9.7
Fwd EY4.27%
FCF(TTM)11.85
FCFY5.22%
OCF(TTM)18.39
OCFY8.1%
SpS90.72
BVpS238.45
TBVpS213.07
PEG (NY)N/A
PEG (5Y)2.74
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.71% | ||
| ROE | -32.4% | ||
| ROCE | 3.42% | ||
| ROIC | 2.7% | ||
| ROICexc | 3.31% | ||
| ROICexgc | 3.67% | ||
| OM | 12.14% | ||
| PM (TTM) | N/A | ||
| GM | 53.68% | ||
| FCFM | 13.07% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.19%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexcg growth 3Y8.28%
ROICexcg growth 5Y0.09%
ROICexc growth 3Y5.96%
ROICexc growth 5Y-0.55%
OM growth 3Y-15.52%
OM growth 5Y1.14%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.62 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.2% | ||
| Interest Coverage | -6.57 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.99 | ||
| Quick Ratio | 4.43 | ||
| Altman-Z | 3.13 |
F-Score5
WACC9.74%
ROIC/WACC0.28
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.76%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.49%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%10.92%
EPS Next Y-15.61%
EPS Next 2Y-3.01%
EPS Next 3Y2.58%
EPS Next 5Y-4.33%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%-4.16%
Revenue Next Year-2.11%
Revenue Next 2Y0.75%
Revenue Next 3Y1.79%
Revenue Next 5Y1.35%
EBIT growth 1Y-9.77%
EBIT growth 3Y-19.1%
EBIT growth 5Y3.28%
EBIT Next Year22.43%
EBIT Next 3Y13.71%
EBIT Next 5Y6.41%
FCF growth 1Y162.24%
FCF growth 3Y-20.82%
FCF growth 5Y-5.84%
OCF growth 1Y112.81%
OCF growth 3Y-12.08%
OCF growth 5Y-0.13%